Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC201 in Neuroendocrine Tumors
NCT03034200Phase 2Completed
- Start
- Aug 2017
- Primary completion
- May 2023
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dordaviprone in Neuroendocrine Neoplasm (NEN), pheochromocytoma, Paraganglioma (PGL), desmoplastic small round cell tumor (DSRCT), Ewing sarcoma. Started Aug 2017; status: completed.
02
Drugs
dordaviprone
03
Conditions
Neuroendocrine Neoplasm (NEN)pheochromocytomaParaganglioma (PGL)desmoplastic small round cell tumor (DSRCT)Ewing sarcoma
Beyond the preview
Go deeper on NCT03034200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03034200.